Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 10/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.47 |
| ▸ | CDK2 | P24941 | 5/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | CDK7 | P50613 | 1/20 | 0.44 |
| ▸ | CCNH | P51946 | 1/20 | 0.44 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL560159 | 1.00 | MAPK1 (0.50) | MAPK1CCNE1CDK2HPGDSNPC1 | |
| SCHEMBL2257862 | 0.87 | CCNE1 (0.47) | MAPK1CCNE1CDK2CDK7CCNH | |
| SCHEMBL559327 | 0.87 | CCNE1 (0.47) | MAPK1CCNE1CDK2CDK7CCNH | |
| SCHEMBL2259332 | 0.82 | NPC1 (0.53) | MAPK1CCNE1CDK2NPC1RAB9A | |
| SCHEMBL559575 | 0.82 | NPC1 (0.53) | MAPK1CCNE1CDK2NPC1RAB9A | |
| SCHEMBL560324 | 0.82 | CDK7 (0.55) | MAPK1CCNE1CDK2CDK7CCNH | |
| SCHEMBL560325 | 0.82 | CDK7 (0.55) | MAPK1CCNE1CDK2CDK7CCNH | |
| SCHEMBL2255142 | 0.82 | SMN1; SMN2 (0.48) | CCNE1CDK2NPC1RAB9A | |
| SCHEMBL558885 | 0.82 | SMN1; SMN2 (0.48) | CCNE1CDK2NPC1RAB9A | |
| SCHEMBL559092 | 0.81 | HPGDS (0.51) | MAPK1CCNE1CDK2HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | MAPK1 1/4885CCNE1 523/4885CDK2 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.